Chordia Therapeutics, Inc.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
CLK (CDC-like kinase family)Small molecule
Acute Myeloid Leukemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
RogocekibPhase 1/2Acute Myeloid Leukemia, Myelodysplastic Syndromes
Est. primary completion 2028-06 · NCT05732103 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 June 2026PresentationCTX-712 (rogocekib)Phase 1/2 dose-escalation data presented at EHA 2026
Chordia Therapeutics Inc · Source ↗

Financial reports

Quarterly & interim (2)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$5.3M$16M—report ↗
View 1 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1—$5.3M$22M—report ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$9.6M$17M—report ↗

Chordia Therapeutics, Inc. reported R&D spend of $9.56M, down 3.8% YoY, cash and equivalents of $17.34M, and a net loss of $11.97M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$9.9M$30M—report ↗